rs-102221 rs-102221 rs-102221 is a drug developed by hoffmann–la roche, which was one of the first compounds discovered that acts as a potent and selective antagonist at the serotonin 5-ht2c receptor, with around 100x selectivity over the closely related 5-ht2a and 5-ht2b receptors. it has anxiolytic effects in animal studies, increases the effectiveness of ssri antidepressants, and shows a complex interaction with cocaine, increasing some effects but decreasing others, reflecting a role for the 5-ht2c receptor in regulation of the dopamine signalling system in the brain. rs-102221clinical dataother namesrs-102,221; 8--1,3,8-triazaspirodecane-2,4-dioneidentifiers iupac name n--4-(trifluoromethyl)benzenesulfonamide cas number185376-97-0 ypubchem cid3693566iuphar/bps187chemspider2925610chemblchembl88402 nchemical and physical dataformulac27h33f3n4o7smolar mass614.64 g·mol−13d model (jsmol)interactive image smiles c4cc(c(f)(f)f)ccc4s(=o)(=o)nc(c(oc)cc2oc)cc2c(=o)ccccn(cc3)ccc13nc(=o)nc1=o inchi inchi=1s/c27h31f3n4o7s/c1-40-22-16-23(41-2)20(33-42(38,39)18-8-6-17(7-9-18)27(28,29)30)15-19(22)21(35)5-3-4-12-34-13-10-26(11-14-34)24(36)31-25(37)32-26/h6-9,15-16,33h,3-5,10-14h2,1-2h3,(h2,31,32,36,37)key:hzzzzodvdshqrg-uhfffaoysa-n ny (what is this?) (verify)